CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Dror Bashan

Chief Executive Officer, Protalix BioTherapeutics

Search every verified Dror Bashan interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Dror Bashan, Chief Executive Officer of Protalix Biotherapeutics, has outlined the company’s strategic priorities for 2025, focusing on advancing its ProCellEx plant-cell platform and addressing unmet medical needs in renal diseases. In January 2025, he discussed the company’s plans to pursue a selected renal indication, building on experience gained from Fabry disease development, and to explore high-end innovative technologies to combine with the platform, which he described as creating “Protalix 3.0.” Bashan also highlighted the successful completion of a Phase 1 clinical trial for PRX-115, a gout treatment candidate, with plans to initiate a Phase 2 study by mid-2025. Bashan has repeatedly emphasized the company’s improved financial position, stating that Protalix became debt-free as of September 2024 after paying approximately $65 million in cash and $15 million in interest over five years. He reported $45 million in cash at the end of Q2 2024 and expressed confidence that the company has sufficient funds, alongside partnership revenues, to maintain operations. In earlier appearances, Bashan discussed the company’s commercial products for Gaucher and Fabry diseases, the regulatory status of PRX-102, and the role of partner Chiesi in building a rare disease business.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →